ID
IDT.AX
—
ASX
Pharmaceuticals
IDT Australia Ltd
LatestGenesis Capital probes Mayne Pharma's Adelaide plant amid investor pressure for break-up
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
13,7M AUD
P/E
—
EV / Rev
1,2x
Div yield
—
Op margin
-42,2 %
ROE
-24,7 %
Net margin
-38,3 %
Debt / equity
0,48
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
2026-09-09
Ex-dividend
—
TR 1Y
—
About
IDT Australia Ltd operates in the pharmaceuticals sector, generating revenue through its healthcare-related activities.
Business. IDT Australia Ltd (IDT.AX) is a pharmaceutical company operating within the Health Care sector. The firm is headquartered in Australia and is primarily listed on the Australian Securities Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Classification85 %
SectorHealth Care
Industry groupPharmaceuticals
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership
—
not yet wired
Profitability→
-24,7 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
1Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to IDT.AX. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsFY 2026 earnings (expected)2026-09-09 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · 2026-07-16
Composite-score breakdown
Synthesis
Business
IDT Australia Ltd (IDT.AX) is a pharmaceutical company operating within the Health Care sector. The firm is headquartered in Australia and is primarily listed on the Australian Securities Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Classification85 %
SectorHealth Care
Industry groupPharmaceuticals
AI synthesis
GENERATEDIDT Australia Ltd maintains a capital structure characterized by AUD 10.4 million in long-term debt against AUD 21.9 million in total equity, resulting in a debt-to-equity ratio of 0.48. The company holds a current ratio of 2.94, indicating sufficient short-term liquidity to cover immediate obligations. However, the firm reports negative net cash after subtracting total debt, which contributes to a medium liquidity risk assessment. The market capitalization stands at AUD 13.7 million, with a price-to-book ratio of 0.62, suggesting the market values the company below its book value.
Profitability metrics reflect significant operational challenges, with a net income of -AUD 8.1 million and an operating income of -AUD 7.3 million. The return on equity is -24.73%, and the return on assets is -14.66%, indicating that the company is currently destroying shareholder value and failing to generate returns on its asset base. The gross profit of AUD 13.7 million on revenue of AUD 19.9 million suggests a gross margin of approximately 69%, but this is insufficient to cover operating expenses, leading to substantial operating losses.
Key takeaways
- The company reports a net loss of AUD 8.1 million, with negative returns on equity (-24.73%) and assets (-14.66%).
- Liquidity is assessed as medium risk, with a current ratio of 2.94 but negative net cash after debt.
- Dilution risk is low, with no difference between basic and diluted shares outstanding.
- Free cash flow is negative at -AUD 8.5 million, indicating ongoing cash burn.
- The market values the company at 0.62x book value, reflecting investor skepticism about profitability.
- Lack of historical and segment data limits comprehensive growth and concentration analysis.
Bull / Bear case
Generated · model-assistedBULL CASE · 5
Revenue grew 8.7% annually over four years, demonstrating consistent top-line expansion despite recent volatility.
Gross profit reached AUD 13.7 million in the latest period, indicating strong underlying product margins.
Cash conversion ratio of 1.77 exceeds the pharmaceutical cohort median of 0.95, showing superior efficiency.
Debt-to-equity ratio of 0.48 is below the cohort median of 0.18, suggesting manageable leverage levels.
Dilution risk is assessed as low, providing some protection for existing shareholder equity value.
BEAR CASE · 4
Net income deteriorated significantly to a loss of AUD 8.1 million in the latest fiscal period.
Free cash flow turned deeply negative at AUD 8.5 million, highlighting severe cash burn issues.
Return on equity of -24.7% ranks in the bottom quartile, indicating poor capital efficiency.
Credit risk is flagged as high, signaling potential difficulties in meeting financial obligations.
In focus — financials by report
Annual
ANNUALFiled 2024-08-26
FY 2024 · Full-year highlights
Revenue A$14.1M, +100,8% YoY; Operating income +39,1% YoY.
RevenueA$14.1M+100,8 % YoY
Operating income-A$6.0M+39,1 % YoY
Net income-A$5.4M+36,3 % YoY
Free cash flow-A$5.2M+35,1 % YoY
EPS—
Operating cash flow-A$9.6M−21,5 % YoY
Financials
Income statement
RevenueA$14.1M
Gross profitA$11.3M
Operating income-A$6.0M
Net income-A$5.4M
Margins
Gross margin80.1%
Operating margin-42.2%
Net margin-38.3%
FCF margin-36.7%
Balance sheet
Total assetsA$31.4M
Total liabilitiesA$7.9M
Total equityA$23.4M
Cash & equivalents—
Long-term debtA$4.5M
Cash flow
Operating cash flow-A$9.6M
CapEx-A$694.0k
Free cash flow-A$5.2M
SBC—
P&L flow · revenue → net income
Highlights
- ▍Revenue A$14.1M, +100,8% YoY
- ▍Operating income +39,1% YoY
- ▍Net income +36,3% YoY
- ▍Free cash flow +35,1% YoY
- ▍Net margin -38.3%
ANNUALFiled 2023-08-29
FY 2023 · Full-year highlights
Revenue A$7.0M, −42,0% YoY; Operating income −421,1% YoY.
RevenueA$7.0M−42,0 % YoY
Operating income-A$9.8M−421,1 % YoY
Net income-A$8.5M−632,6 % YoY
Free cash flow-A$8.0M−1 389,0 % YoY
EPS—
Operating cash flow-A$7.9M−376,2 % YoY
Financials
Income statement
RevenueA$7.0M
Gross profitA$4.9M
Operating income-A$9.8M
Net income-A$8.5M
Margins
Gross margin69.0%
Operating margin-139.0%
Net margin-120.8%
FCF margin-113.5%
Balance sheet
Total assetsA$28.3M
Total liabilitiesA$4.1M
Total equityA$24.1M
Cash & equivalents—
Long-term debtA$740.0k
Cash flow
Operating cash flow-A$7.9M
CapEx-A$522.0k
Free cash flow-A$8.0M
SBC—
P&L flow · revenue → net income
Highlights
- ▍Revenue A$7.0M, −42,0% YoY
- ▍Operating income −421,1% YoY
- ▍Net income −632,6% YoY
- ▍Free cash flow −1 389,0% YoY
- ▍Net margin -120.8%
ANNUALFiled 2022-08-30
FY 2022 · Full-year highlights
Revenue A$12.1M, −28,3% YoY; Operating income −294,2% YoY.
RevenueA$12.1M−28,3 % YoY
Operating income-A$1.9M−294,2 % YoY
Net income-A$1.2M−155,2 % YoY
Free cash flow-A$536.0k−116,0 % YoY
EPS—
Operating cash flowA$2.9M+673,2 % YoY
Financials
Income statement
RevenueA$12.1M
Gross profitA$10.7M
Operating income-A$1.9M
Net income-A$1.2M
Margins
Gross margin88.1%
Operating margin-15.5%
Net margin-9.6%
FCF margin-4.4%
Balance sheet
Total assetsA$30.1M
Total liabilitiesA$3.1M
Total equityA$27.0M
Cash & equivalents—
Long-term debtA$881.0k
Cash flow
Operating cash flowA$2.9M
CapEx-A$912.0k
Free cash flow-A$536.0k
SBC—
P&L flow · revenue → net income
Highlights
- ▍Revenue A$12.1M, −28,3% YoY
- ▍Operating income −294,2% YoY
- ▍Net income −155,2% YoY
- ▍Free cash flow −116,0% YoY
- ▍Net margin -9.6%
Valuation FY
Market price
A$0,03
Market cap
A$13.7M
Enterprise valueⓘ
A$24.1M
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
1.2x
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
0.6x
P / Tangible bookⓘ
0.6x
Tangible book
A$21.9M
Net cashⓘ
-A$10.4M
Current ratioⓘ
2.9
Debt / equityⓘ
0.5
ROAⓘ
-14.7%
ROEⓘ
-24.7%
Cash conversionⓘ
177.0%
CapEx / revenueⓘ
-4.9%
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
Business relationships28 disclosed relationships · 1 type · extracted from filings & disclosures
Subsidiaries28
EX21:0c150c3601e2EX21:0c150c3601e2Subsidiarie97%
EX21:114c29da4453EX21:114c29da4453Subsidiarie97%Source ↗
EX21:13425bd9e339EX21:13425bd9e339Subsidiarie97%Source ↗
EX21:1ef7a61185b3EX21:1ef7a61185b3Subsidiarie97%Source ↗
EX21:28877ae869afEX21:28877ae869afSubsidiarie97%Source ↗
EX21:2a9a06eba13aEX21:2a9a06eba13aSubsidiarie97%
EX21:408c7c5887a0EX21:408c7c5887a0Subsidiarie97%Source ↗
EX21:455fe3305791EX21:455fe3305791Subsidiarie97%
EX21:4e53206df985EX21:4e53206df985Subsidiarie97%
EX21:4f0bf87cc939EX21:4f0bf87cc939Subsidiarie97%Source ↗
EX21:5498ec036143EX21:5498ec036143Subsidiarie97%
EX21:581447b3947eEX21:581447b3947eSubsidiarie97%
EX21:6038ac4d7893EX21:6038ac4d7893Subsidiarie97%Source ↗
EX21:66d88a1e9a51EX21:66d88a1e9a51Subsidiarie97%
EX21:71fcbd2b7020EX21:71fcbd2b7020Subsidiarie97%Source ↗
EX21:8001c2743965EX21:8001c2743965Subsidiarie97%Source ↗
EX21:81cfdf709731EX21:81cfdf709731Subsidiarie97%
EX21:8823f192dbafEX21:8823f192dbafSubsidiarie97%
EX21:908e3714f033EX21:908e3714f033Subsidiarie97%Source ↗
EX21:969bc939ea57EX21:969bc939ea57Subsidiarie97%Source ↗
EX21:96d74dd4c801EX21:96d74dd4c801Subsidiarie97%
EX21:abe18c4aea7eEX21:abe18c4aea7eSubsidiarie97%Source ↗
EX21:c7e4f184f7a9EX21:c7e4f184f7a9Subsidiarie97%
EX21:d47cc97845beEX21:d47cc97845beSubsidiarie97%
EX21:d4e70701bb50EX21:d4e70701bb50Subsidiarie97%
EX21:dbe963d0b046EX21:dbe963d0b046Subsidiarie97%
EX21:ed43eedef13bEX21:ed43eedef13bSubsidiarie97%Source ↗
EX21:ee7ac1cc9a77EX21:ee7ac1cc9a77Subsidiarie97%
Supply chain
— missing data
Peer comparison
— missing data
Market position
Stress test
— missing data
Predictor forecast
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
— missing data
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskMedium
Filing-based flags
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Op Margin-42,2 %Bottom quartile
Net Margin-38,3 %Bottom quartile
ROE-24,7 %Bottom quartile
Capex / Rev-4,9 %Above median
D/E0,48Below median
Cash Conv1,77Above median
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net disposed 7 370 sh2 exercises · 1 grants3 insiders
- EVP of Strategic&Legal Affairs · Deferred Stock Units → Class B Common StockDisposed 4 166exercise · 2026-02-17
- Chief Financial Officer · Employee Stock Option (right to buy) → Class B Common StockDisposed 5 204 @ $38,43exercise · 2026-01-16
- EVP and Corporate Secretary · Deferred Stock Units → Class B Common StockAcquired 2 000grant · 2025-09-18
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Reference data
How metrics are computed
- Price To Tangible Bookmarket_price / (tangible_book_value / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Return On Equitynet_income / total_equity
- Enterprise Valuemarket_cap - net_cash
- Ev To Revenueenterprise_value / revenue
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
Source documents
- IDT Australia Ltd Market data — financials · 2026-07-17
Ownership & reference
Leadership
- Mark Anthony SimariExecutive Chairman of the Board
Insider activity
Net selling0 buys · 19 sellsnet -$6,7M10 insiders · last 365d
- EVP and Corporate Secretary · Class B Common Stock, par value $.01 per shareSold 505 @ $62,58$32K · 2026-07-17
- EVP and Corporate Secretary · Class B Common Stock, par value $.01 per shareSold 3 488 @ $62,56$218K · 2026-07-17
- EVP of Strategic&Legal Affairs · Class B Common Stock, $.01 par value per shareSold 3 653 @ $63,17$231K · 2026-07-16
- EVP of Strategic&Legal Affairs · Class B Common Stock, $.01 par value per shareSold 4 397 @ $63,02$277K · 2026-07-15
- Director · Class B Common Stock, $.01 par value per shareSold 500 @ $57,78$29K · 2026-06-30
- Chief Financial Officer · Class B Common Stock, $.01 par value per shareSold 23 323 @ $56,98$1,3M · 2026-06-26
- Director, Chairman, 10% owner · Class B Common Stock, $.01 par value per shareOther 2 217 · 2026-06-23
- Former Director · Class B Common Stock, par value $.01 per shareSold 2 408 @ $55,03$133K · 2026-06-11
- Director · Class B Common Stock, $.01 par value per shareOther 673 @ $55,75$38K · 2026-06-09
- EVP of GLOBAL HUMAN RESOURCES · Class B Common Stock, par value $.01 per shareSold 500 @ $55,32$28K · 2026-06-08
- Director, Chairman, 10% owner · Class B Common Stock, $.01 par value per shareOther 7 942 · 2026-05-07
- EVP and Corporate Secretary · Class B Common Stock, par value $.01 per shareOther 722 · 2026-05-07
- Director, Chairman, 10% owner · Class B Common Stock, $.01 par value per shareOther 1 175 · 2026-05-05
- EVP and Corporate Secretary · Class B Common Stock, par value $.01 per shareSold 2 297 @ $50,94$117K · 2026-04-16
- EVP and Corporate Secretary · Class B Common Stock, par value $.01 per shareSold 907 @ $50,94$46K · 2026-04-16
- Director, Chairman, 10% owner · Class B Common Stock, $.01 par value per shareOther 600 · 2026-04-16
- EVP of Strategic&Legal Affairs · Class B Common Stock, $.01 par value per shareSold 20 000 @ $51,00$1,0M · 2026-04-14
- Chief Financial Officer · Class B Common Stock, par value $.01 per shareSold 5 000 @ $50,50$252K · 2026-04-14
- EVP of Strategic&Legal Affairs · Class B Common Stock, $.01 par value per shareOther 347 @ $48,45$17K · 2026-02-17
- EVP of Strategic&Legal Affairs · Class B Common Stock, $.01 par value per shareOther 834 @ $48,45$40K · 2026-02-17
- Director, Chairman, 10% owner · Class B Common Stock, $.01 par value per shareOther 2 214 · 2026-01-28
- EVP and Corporate Secretary · Class B Common Stock, par value $.01 per shareSold 2 505 @ $50,28$126K · 2026-01-16
- Chief Financial Officer · Class B Common Stock, par value $.01 per shareOther 5 204 @ $38,43$200K · 2026-01-16
- Director, COO & President · Class B Common Stock, $.01 par value per shareSold 7 287 @ $51,17$373K · 2026-01-15
- Chief Financial Officer · Class B Common Stock, par value $.01 per shareSold 920 @ $52,04$48K · 2026-01-15
Short positioning
486.4Kshares short-6.9% vs prior
2.56days to cover
47.7%short of daily vol
60fails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
IDT.AXCanonical
ASX · AUD
Intel & risk
peak dispatch · 2026-07-16
OSINT findings
Dilution riskLow
Liquidity riskMedium
Net cash is negative after subtracting total debt.
Relationship graph
This companySectorSubsidiaries
Evidence & claims
From filings & derived data- Total liabilities (annual): USD 310.09MUnknown
- Current liabilities (annual): USD 308.41MUnknown
- Total assets (annual): USD 678.29MUnknown
- Current assets (annual): USD 572.8MUnknown
- Cash & equivalents (annual): USD 210.18MUnknown
- Shareholders' equity (annual): USD 339.74MUnknown
- Cost of revenue (annual): USD 785.3MUnknown
- R&D expense (annual): USD 50.96MUnknown
- Total operating expenses (annual): USD 345.77MUnknown
- EPS (diluted) (annual): USD-PER-SHARES 3Unknown
- Net income (annual): USD 76.09MUnknown
- Gross profit (annual): USD 446.19MUnknown
- Capex (annual): USD 20.77MUnknown
- Pre-tax income (annual): USD 105.84MUnknown
- Revenue (annual): USD 1.23BUnknown
- Operating cash flow (annual): USD 127.06MUnknown
- Operating income (annual): USD 100.42MUnknown
- EPS (basic) (annual): USD-PER-SHARES 3Unknown
- Total assets (annual): USD 575.73MUnknown
- Current liabilities (annual): USD 278.19MUnknown
- Cash & equivalents (annual): USD 142.15MUnknown
- Current assets (annual): USD 462.13MUnknown
- Shareholders' equity (annual): USD 271.6MUnknown
- Total liabilities (annual): USD 280.63MUnknown
Showing 24 of 34 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-09-09EVENTUpcomingFY 2026 earnings (expected) estimated date
2026-07-17INSIDERMASON JOYCE J sold 505 sh Class B Common Stock, par value $.01 per share — EVP and Corporate Secretary ~$32k
2026-07-17INSIDERMASON JOYCE J sold 3.5k sh Class B Common Stock, par value $.01 per share — EVP and Corporate Secretary ~$218k
2026-07-16 14:54 UTCNEWSGenesis Capital probes Mayne Pharma's Adelaide plant amid investor pressure for break-up →
2026-07-16INSIDERASH MENACHEM sold 3.7k sh Class B Common Stock, $.01 par value per share — EVP of Strategic&Legal Affairs ~$231k
2026-07-15INSIDERASH MENACHEM sold 4.4k sh Class B Common Stock, $.01 par value per share — EVP of Strategic&Legal Affairs ~$277k
2026-06-30INSIDERCOSENTINO ERIC F. sold 500 sh Class B Common Stock, $.01 par value per share — Director ~$29k
2026-06-26INSIDERFISCHER MARCELO sold 23.3k sh Class B Common Stock, $.01 par value per share — Chief Financial Officer ~$1.33M
2026-06-23 00:00 UTCINSIDER4 insider transactions — 2026-06 · net sell $123k
2026-06-23INSIDERJONAS HOWARD S transacted 2.2k sh Class B Common Stock, $.01 par value per share — Director, Chairman, 10% owner
2026-06-11INSIDERKATSOF IRWIN sold 2.4k sh Class B Common Stock, par value $.01 per share — Former Director ~$133k
2026-06-09INSIDERCONKLING WILLIAM transacted 673 sh Class B Common Stock, $.01 par value per share — Director ~$38k
2026-06-08INSIDERSHEA NADINE sold 500 sh Class B Common Stock, par value $.01 per share — EVP of GLOBAL HUMAN RESOURCES ~$28k
2026-05-07 00:00 UTCINSIDER3 insider transactions — 2026-05
2026-05-07INSIDERJONAS HOWARD S transacted 7.9k sh Class B Common Stock, $.01 par value per share — Director, Chairman, 10% owner
2026-05-07INSIDERMASON JOYCE J transacted 722 sh Class B Common Stock, par value $.01 per share — EVP and Corporate Secretary
2026-05-05INSIDERJONAS HOWARD S transacted 1.2k sh Class B Common Stock, $.01 par value per share — Director, Chairman, 10% owner
2026-04-16 00:00 UTCINSIDER5 insider transactions — 2026-04 · net sell $1.4M
2026-04-16INSIDERMASON JOYCE J sold 2.3k sh Class B Common Stock, par value $.01 per share — EVP and Corporate Secretary ~$117k
2026-04-16INSIDERMASON JOYCE J sold 907 sh Class B Common Stock, par value $.01 per share — EVP and Corporate Secretary ~$46k
2026-04-16INSIDERJONAS HOWARD S transacted 600 sh Class B Common Stock, $.01 par value per share — Director, Chairman, 10% owner
2026-04-14INSIDERASH MENACHEM sold 20.0k sh Class B Common Stock, $.01 par value per share — EVP of Strategic&Legal Affairs ~$1.02M
2026-04-14INSIDERFISCHER MARCELO sold 5.0k sh Class B Common Stock, par value $.01 per share — Chief Financial Officer ~$252k
2026-02-17 00:00 UTCINSIDER3 insider transactions — 2026-02 1 derivative
2026-02-17INSIDERASH MENACHEM transacted 347 sh Class B Common Stock, $.01 par value per share — EVP of Strategic&Legal Affairs ~$17k
2026-02-17INSIDERASH MENACHEM transacted 834 sh Class B Common Stock, $.01 par value per share — EVP of Strategic&Legal Affairs ~$40k
2026-02-17INSIDERASH MENACHEM disposed of 834 sh Deferred Stock Units — EVP of Strategic&Legal Affairs
2026-01-28 00:00 UTCINSIDER11 insider transactions — 2026-01 · net sell $595k 1 derivative
2026-01-28INSIDERJONAS HOWARD S transacted 2.2k sh Class B Common Stock, $.01 par value per share — Director, Chairman, 10% owner
2026-01-16INSIDERMASON JOYCE J sold 2.5k sh Class B Common Stock, par value $.01 per share — EVP and Corporate Secretary ~$126k
2026-01-16INSIDERFISCHER MARCELO transacted 5.2k sh Class B Common Stock, par value $.01 per share — Chief Financial Officer ~$200k
2026-01-16INSIDERFISCHER MARCELO disposed of 5.2k sh Employee Stock Option (right to buy) — Chief Financial Officer
2026-01-15INSIDERPEREIRA BILL sold 7.3k sh Class B Common Stock, $.01 par value per share — Director, COO & President ~$373k
2026-01-15INSIDERFISCHER MARCELO sold 920 sh Class B Common Stock, par value $.01 per share — Chief Financial Officer ~$48k
Showing the 40 most recent of 53 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data
Premium coverage